Share on StockTwits

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) were the target of a significant decline in short interest in the month of June. As of June 13th, there was short interest totalling 432,812 shares, a decline of 25.9% from the May 30th total of 584,343 shares, American Banking News.com reports. Based on an average trading volume of 178,623 shares, the days-to-cover ratio is currently 2.4 days. Currently, 5.0% of the shares of the stock are sold short.

AERI has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Aerie Pharmaceuticals from $27.00 to $36.00 in a research note on Thursday, June 26th. They now have an “outperform” rating on the stock. Separately, analysts at Needham & Company LLC raised their price target on shares of Aerie Pharmaceuticals from $26.00 to $37.00 in a research note on Thursday, June 26th. They now have a “buy” rating on the stock.

Aerie Pharmaceuticals (NASDAQ:AERI) opened at 23.99 on Thursday. Aerie Pharmaceuticals has a 52 week low of $10.25 and a 52 week high of $29.71. The stock’s 50-day moving average is $18.44 and its 200-day moving average is $18.65. The company’s market cap is $562.3 million.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings data on Monday, May 12th. The company reported ($0.28) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.35) by $0.07. Analysts expect that Aerie Pharmaceuticals will post $-1.49 EPS for the current fiscal year.

Aerie Pharmaceuticals, Inc is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.